The 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21st and 22nd May 2010 with the participation of a multidisciplinary panel of leading professionals in pathology and molecular diagnostics and medical, surgical and radiation oncology. Before the conference, the expert panel prepared clinically relevant questions concerning five areas as follows: early and locally advanced non-small-cell lung cancer (NSCLC), first-line metastatic NSCLC, second-/third-line NSCLC, NSCLC pathology and molecular testing, and small-cell lung cancer (SCLC) to be addressed through discussion at the Consensus Conference. All relevant scientific literature for each question was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The consensus agreement in SCLC is reported in this article. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update. 1 -Early and locally advanced non-small-cell lung cancer (NSCLC) 2 -NSCLC pathology and molecular testing 3 -First-line metastatic NSCLC 4 -Second-/third-line NSCLC 5 -Small-cell lung cancer (SCLC)
Five working groups were appointed, each comprised six to eight participants with multidisciplinary involvement and led by a chair, and with the assistance of one expert in methodological aspects. A total of 39 experts were involved in this consensus process (see Panel members listed in the Appendix).
The 1st ESMO Consensus Conference on Lung Cancer was held in May 2010 in Lugano. Before the conference, each group identified a number of clinically relevant questions suitable for consensus discussion and provided the available literature. At the Conference, in five parallel sessions, each group discussed and reached agreement on the questions previously chosen. Decisions were made using studies published in peer review journals. If no relevant published data were identified, expert opinions were considered. The consideration of abstracts was at the discretion of the groups. All relevant scientific literature, as identified by the experts, was considered. A systematic literature search was not carried out. The recommendations from each group were then presented to all the experts and discussed, and a general consensus was reached. The 'Infectious Diseases Society of American-United States Public Health Service Grading System' was used (shown in Tables 1 and 2) for level of evidence and strength of recommendation for each question raised [1] .
The consensus in SCLC is detailed here. SCLC remains an important focus for treatment and research. The SCLC ESMO Guidelines 2010 [2] were endorsed and should be read in conjunction with these additional comments on specific patient situations. Table 3 provides a summary of panel recommendations. The final recommendations listed here have been approved by all participants.
STAGING ISSUES

What is limited stage?
Limited stage should be based on the TNM (tumour-node-metastasis) 7 classification i.e. T1-4 N0-3 M0 [3] . In the new IASLC (International Association for the Study of Lung Cancer) staging system, the largest difference in patient outcomes was observed in patients with N1 versus N2 disease (19 versus 14 months median survival, hazard ratio = 1.40, P = 0.0001) [4] . Furthermore, tumour size was of particular prognostic relevance in patients with N0/N1.
Recommendation 1: The new TNM 7 staging system for NSCLC is to be adopted for SCLC.
Strength of recommendation: A Level of evidence: I
Use of FDG-PET
Several studies have suggested that the old distinction between limited and extensive stage can be improved with positron 
TREATMENT ISSUES: FIRST-LINE TREATMENT
The figure shows a treatment algorithm using the new TNM 7 staging classification.
Should surgery be considered for any specific subgroup?
Several retrospective reports on surgically treated early SCLC patients indicated relatively favourable outcomes of this approach if there was no mediastinal lymph node involvement [9] [10] [11] . Randomised clinical trials addressing the role of surgery and adjuvant chemotherapy versus combined chemoradiotherapy in node-negative SCLC are lacking. The panel believes that these retrospective data are consistent enough to consider surgical approach in selected and adequately staged SCLC patients. Recommendation 4: In patients with clinical T1-2 N0-1 stage who are potential surgical patients, mediastinal node exploration should be carried out. Surgery may be indicated in patients with no mediastinal involvement; resection should be followed by chemotherapy. Postoperative radiotherapy should be considered for pathologic N1 and unforeseen N2 disease.
Strength of recommendation: C Level of evidence: V
What is the treatment of choice for chemotherapy-naive patients with M1 disease?
Platinum/etoposide chemotherapy is a standard as outlined in the 2010 ESMO recommendations [2] . A recent Patients with good PS are eligible for early concurrent thoracic radiotherapy in cycle 1 or 2 [2, 14] . Computed tomography (CT)-based three-dimensional conformal radiotherapy is recommended. Use of FDG-PET for target volume definition is being evaluated. There is no standard dose that may vary between 45 Gy (twice daily) and 55-70 Gy (once daily). Trials exploring the optimal dose and fractionation are ongoing. There are no specific recommendations for SCLC in terms of normal tissue constraints. Based on NSCLC data, both V20 corresponding to the percentage of normal lung parenchyma receiving 20 Gy and the mean lung dose (MLD) should be recorded as they correlate with the risk of radiation pneumonitis [15] . As target volumes may be large, a V20 level of 35%-40% or an MLD of 20-23 Gy can be considered acceptable, but some patients (10%-15%) may develop severe radiation-induced toxicity [16] . Recent studies have explored an involved-field approach without elective irradiation [17] [18] [19] . Furthermore, in subgroup analysis of prospective trials, elderly patients with good PS seem to have similar outcomes to younger patients and age does not appear to impact on efficacy [20] [21] [22] . Toxicity, particularly haematological may be greater among the elderly.
Recommendation 6: Limited-stage patients with good PS should be considered for concomitant chemoradiotherapy, taking into account the feasibility of radiation treatment plan and good planning target volume coverage while maintaining normal tissue dose constraints.
Strength of recommendation: A Level of evidence: II
Other special metastatic situations
A single-centre five-arm randomised study indicated a 5.4% 5-year improvement in a subgroup of patients with metastatic disease who had either a complete or partial response within the thorax and complete remission of distant disease after initial chemotherapy with the use concomitant thoracic radiotherapy and chemotherapy versus chemotherapy alone [23] . The hypothesis generated by this subgroup analysis is being addressed in a phase III multicentre study. Recommendation 7: Thoracic radiotherapy given either concomitantly or sequentially is currently not recommended in patients with distant metastases that have responded to chemotherapy.
Strength of recommendation: C Level of evidence: II
Brain metastases as the only metastatic site
When the brain is the only documented metastatic site of disease, the use of whole-brain radiotherapy and thoracic radiotherapy in addition to chemotherapy may lead to more favourable results, based on a small retrospective study of 30 patients [24] . Data from a prospective study are needed to support the observation. Recommendation 8: In patients with brain involvement as the only metastatic site responding to chemotherapy, concomitant chemotherapy with thoracic radiotherapy is currently not recommended.
Strength of recommendation: C Level of evidence: IV special article Annals of Oncology 9. Which patients should be considered for prophylactic cranial irradiation?
Prophylactic cranial irradiation (PCI) is recommended at the end of initial therapy for patients with a tumour response and no contraindications for this procedure. It is important to define tumour response for consideration of PCI [25] [26] [27] . Although chest X-ray was most often used in the older trials included in the meta-analysis [25] , the panel believes the restaging should be done with the use of CT scan. The imaging should be carried out at 3-4 weeks after the end of initial treatment, as at this stage the determination of tumour response is not yet hampered by the radiotherapy-induced fibrosis. Recommendation 9: PCI is recommended for patients with tumour response. Response should be determined by a restaging CT scan.
Role of PCI in older patients
The mean age in the PCI meta-analysis was 59 with 25% of patients being 65 years or older. However, age older than 60-65 is a risk factor for neurocognitive impairment [28, 29] . Recommendation 10: PCI in older patients, 65 years and older, requires to balance the benefit and risk of possible neurocognitive impairment to be considered.
Strength of recommendation: B Level of evidence: II
FOLLOW-UP ISSUES
What is the optimal follow-up?
SCLC is likely to relapse or progress after initial treatment and second-line treatment improves survival in good PS patients [30] . Detecting a relapse or progression before deterioration of PS is therefore a reasonable approach. Long-term survivors may be at risk of second lung cancer that should be histologically confirmed. Recommendation 11: Subsequent follow-up should be at 2-3 months in non-progressing patients at the end of initial treatment and response determination. The actual timing depends on patient circumstances and availability of further treatment. Imaging with CT is preferable.
TREATMENT ISSUES: SECOND-LINE TREATMENT AND BEYOND
The majority of patients with SCLC experience relapse after their initial treatment, with a median survival of 2-3 months without second-line therapy. Although second-line therapy may induce responses in 10%-40% of patients, these are usually short-lived, and the median survival rarely exceeds 6 months [31] . Three categories of disease have been described in the literature regarding the response to initial therapy and the duration of response: sensitive, resistant, and refractory. 'Sensitive' refers to patients who have had a tumour response lasting 90 days or longer. 'Resistant' refers to patients who have recurred within 90 days of completing therapy. 'Refractory' refers to patients with tumours that never responded to first-line therapy or to those who progressed during first-line therapy [30] .
Sensitive disease
Patients having sensitive disease relapsing >90 days after firstline treatment may benefit from retreatment.
Recommendation 12: Retreat with the same regimen that induced their initial response, usually reinduction with platinum/etoposide.
Resistant disease
In patients having resistant disease, topotecan improved overall survival compared with best supportive care [31] . No statistically significant difference in median survival was found in a randomised trial comparing topotecan with combination chemotherapy although topotecan caused less toxicity [32] .
There is no evidence that combination chemotherapy is superior to single-agent regimens. Both oral and i.v. topotecan had similar efficacy but with slight differences in toxicity [33, 34] . obstructed major airway, may benefit from thoracic radiotherapy [35] [36] [37] .
Strength of recommendation: C Level of evidence: IV
Repeat cranial radiotherapy
For recurrence in the brain after PCI or whole-brain radiotherapy, repeat radiotherapy may be useful in carefully selected patients if no systemic treatment options are available [38] [39] [40] [41] [42] . Recommendation 16: Local brain re-irradiation, which may include stereotactic radiotherapy, may be considered in selected patients.
FUTURE
Several trials could influence treatment options in the near future. These include:
The CONVERT and CALGB 30610 trials addressing the dose and fractionation issues of concurrent thoracic chemoradiotherapy in limited-stage SCLC.
The ongoing individual data meta-analysis of early versus late concurrent thoracic radiotherapy and chemotherapy. The CREST Dutch trial addressing the role of thoracic radiotherapy in patients with restricted metastatic disease. Studies addressing the efficacy of novel systemic treatments, including amrubicin and targeted agents.
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